Martinsried/ Munich Medigene AG announces its participation at the following upcoming scientific and investor conferences.
Martinsried/ Munich (pta/30.10.2019/22:00) Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Medigene’s management and/or scientists will be available for one-on-one meetings at these events.
SITC (Society for Immunotherapy of Cancer) 34th Annual Meeting
Date: 6 - 10 November 2019
Location: National Harbor, USA
BIO Europe
Date: 11 - 13 November 2019
Location: Hamburg, Germany
Jefferies London Healthcare Conference
Date: 20 - 21 November 2019
Location: London, UK
Cell Therapy Manufacturing & Gene Therapy Congress
Date: 3 - 6 December 2019
Location: Amsterdam, Netherlands
61st ASH Annual Meeting & Exposition
Date: 7 - 10 December 2019
Location: Orlando, USA
ESMO Immuno-Oncology Congress 2019
Date: 11 - 14 December 2019
Location: Geneva, Switzerland
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Dr Gary Waanders,
Claudia Burmester, Dr Anna Niedl
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
